Actinium Pharmaceuticals Inc (ATNM)
Official siteHEALTHCARE • BIOTECHNOLOGY • AMEX
Market Cap: $51.56M
Last updated: Nov 17, 2026 at 11:04 AM ET
Actinium Pharmaceuticals Inc (ATNM) P/E Ratio & Valuation Multiples
Actinium Pharmaceuticals (ATNM) trades at 4.1x trailing earnings and 1.3x sales. Its P/B of 1.5x is below its 5-year median of 2.9x. Its forward P/E is 8.5x.
Current Multiples
Its forward P/E is above its trailing P/E, which implies earnings per share about 51.8% lower over the next year.
| Multiple | Value |
|---|---|
| P/E (trailing) | 4.1x |
| Forward P/E | 8.5x |
| Price to sales | 1.3x |
| Price to book | 1.5x |
| EV/EBITDA | 1.0x |
| PEG | N/A |
Historical Medians
Against its 10-year medians, its P/B is 55.9% below 3.4x.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/B | 1.5x | 2.9x | 3.4x |
Valuation History
Over the 4 of the 10 year ends shown that have a P/S, its P/S ranged from 48.5x in 2024 to 471.4x in 2025. 2025 was the highest of those years.
| Year end | Price | P/S | P/B |
|---|---|---|---|
| 2025 | $1.36 | 471.4x | 5.4x |
| 2024 | $1.26 | 48.5x | 1.2x |
| 2023 | $5.08 | N/A | 3.9x |
| 2022 | $10.65 | 204.4x | 4.1x |
| 2021 | $6.01 | 53.7x | 1.8x |
| 2020 | $7.80 | N/A | 2.3x |
| 2019 | $6.55 | N/A | 6.7x |
| 2018 | $11.62 | N/A | 5.2x |
| 2017 | $19.94 | N/A | 4.3x |
| 2016 | $26.28 | N/A | 2.7x |
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About ATNM
What is ATNM's forward P/E ratio?
Actinium Pharmaceuticals has a forward P/E ratio of 8.5x.
Is ATNM stock overvalued?
GNG's valuation label for ATNM is Undervalued.
What is ATNM's price to sales ratio?
Actinium Pharmaceuticals has a price to sales ratio of 1.3x.
ATNM pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors